Drug-eluting stents versus bare metal stents
نویسندگان
چکیده
منابع مشابه
Drug-Eluting Versus Bare-Metal Stents
DR. STONE: Welcome to this roundtable discussion. Today, we’ll be focusing on some of the advantages, disadvantages, and nuances of drug-eluting and baremetal stents in the practice of interventional cardiology. My name is Gregg W. Stone; I’m an interventional cardiologist and Professor of Medicine at Columbia University Medical Center and the Cardiovascular Research Foundation in New York City...
متن کاملMeta-analysis comparing drug-eluting stents with bare metal stents.
We performed a meta-analysis of 10 randomized trials of 5,066 patients with 6 to 12 months of follow-up. The summary risk differences excluded any major differences between the 2 types of stents for death (0.12%, 95% confidence interval [CI] -0.34% to 0.58%, p = 0.60) and overall myocardial infarction (0.04%, 95% CI -0.72% to 0.81%, p = 0.91). There was a modest increase in the risk of Q-wave m...
متن کاملDrug-eluting versus bare-metal stents in large coronary arteries.
BACKGROUND Recent data have suggested that patients with coronary disease in large arteries are at increased risk for late cardiac events after percutaneous intervention with first-generation drug-eluting stents, as compared with bare-metal stents. We sought to confirm this observation and to assess whether this increase in risk was also seen with second-generation drug-eluting stents. METHOD...
متن کاملEffect of length and diameter of drug-eluting stents versus bare-metal stents on late outcomes.
BACKGROUND The risk of restenosis and other adverse cardiac events with bare-metal stents (BMS) is increased with smaller stent diameters and longer stent lengths. Drug-eluting stents (DES) may reduce this effect in select patients; however, whether this benefit occurs in high-risk lesions and patients in routine practice is not clear. METHODS AND RESULTS Clinical outcomes (target-vessel reva...
متن کاملDrug-Eluting Stents Versus Bare Metal Stents in Saphenous Vein Graft Intervention.
Percutaneous coronary intervention (PCI) of saphenous vein graft (SVG) is associated with higher adverse event rates, lower procedural success, and inferior longterm patency rates compared with native vessel PCI. The ability to comply with dual antiplatelet therapy, and whether the patient will need an interruption in dual antiplatelet therapy, should be considered when deciding whether to impl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Cardiology
سال: 2003
ISSN: 0160-9289,1932-8737
DOI: 10.1002/clc.4960261102